Payment overview · 2025
General Payments
$37,159.68
71 reported records · 25 companies
Healthcare provider profile · identity verified
Akash Mukherjee, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · CINCINNATI, OH · NPI 1285981498
Verified facts
What the public records show
CMS Open Payments records show Akash Mukherjee, MD received $37,159.68 in general payments during 2025 across 71 reported records.
Kite Pharma, Inc. accounted for 67.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Eliquis, Rezurock, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Venclexta by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brukinsa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REZUROCK as an associated drug or biological on 17 records involving 14 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rezurock by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Venclexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REZUROCK as an associated drug or biological on 1398 records involving 724 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rezurock by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $25,162.71 | 67.7% | 10 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $10,890.53 | 29.3% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $117.42 | 0.3% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $112.11 | 0.3% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $91.17 | 0.2% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $88.22 | 0.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.11 | 0.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.75 | 0.2% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $62.85 | 0.2% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.31 | 0.1% | 3 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $43.89 | 0.1% | 2 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $41.82 | 0.1% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $38.41 | 0.1% | 2 | 2025 |
| SHORLA ONCOLOGY INC. | Unresolved — no canonical attribution shown | $33.50 | 0.1% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.59 | 0.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $30.91 | 0.1% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $29.95 | 0.1% | 1 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.58 | 0.1% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $27.62 | 0.1% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.52 | 0.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.38 | 0.1% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $19.33 | 0.1% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $17.98 | 0.1% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.52 | 0.0% | 1 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $15.50 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,410.00 | 11 |
| Food and Beverage | $1,744.68 | 59 |
| Travel and Lodging | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $25,162.71 | 10 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $10,890.53 | 9 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $112.11 | 6 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $99.21 | 5 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $91.17 | 3 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $91.17 | 3 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $88.22 | 5 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $74.07 | 4 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $66.19 | 3 | 2025 |
Source payment records
|
|||||
| REZUROCK Normalized: rezurock |
Drug | SANOFI-AVENTIS U.S. LLC | $62.85 | 3 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $56.47 | 3 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $56.47 | 3 | 2025 |
Source payment records
|
|||||
| VIVIMUSTA Normalized: vivimusta |
Drug | Azurity Pharmaceuticals, Inc. | $47.31 | 3 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Incyte Corporation | $43.89 | 2 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| IMKELDI Normalized: imkeldi |
Drug | SHORLA ONCOLOGY INC. | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $29.95 | 1 | 2025 |
Source payment records
|
|||||
| SANCUSO Normalized: sancuso |
Drug | Cumberland Pharmaceuticals, Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Venclexta Normalized: venclexta |
Biological | Genentech USA, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Tazverik Normalized: tazverik |
Drug | Ipsen Biopharmaceuticals, Inc | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 31 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
| REZUROCK rezurock |
2025 | Rezurock | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Venclexta venclexta |
2025 | Venclexta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
31 | 13 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 18 |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | REZUROCK open payments reported associated product |
CMS Open Payments — General Payments 17 supporting records · 14 recipient NPIs · example record 1233208487 |
Rezurock · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 18 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | REZUROCK open payments reported associated product |
CMS Open Payments — General Payments 1398 supporting records · 724 recipient NPIs · example record 1233195188 |
Rezurock · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acyclovir | Acyclovir | 107 | 44 |
| Valacyclovir | Valacyclovir Hcl | 90 | 34 |
| Levofloxacin | Levofloxacin | 77 | 36 |
| Prednisone | Prednisone | 62 | 25 |
| Fluconazole | Fluconazole | 54 | 27 |
| Eliquis | Apixaban | 46 | 18 |
| Olanzapine | Olanzapine | 40 | 17 |
| Venclexta | Venetoclax | 37 | 15 |
| Hydroxyurea | Hydroxyurea | 35 | 14 |
| Brukinsa | Zanubrutinib | 31 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | suppressed |
| Tacrolimus | Tacrolimus | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | 15 |
| Dexamethasone | Dexamethasone | 27 | 17 |
| Ursodiol | Ursodiol | 25 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | 15 |
| Revlimid | Lenalidomide | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | 11 |
| Penicillin V Potassium | Penicillin V Potassium | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 14 |
| Dapsone | Dapsone | 15 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Ninlaro | Ixazomib Citrate | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Rezurock | Belumosudil Mesylate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Lenalidomide | Lenalidomide | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37,159.68 · 71 records | Kite Pharma, Inc. | ADCETRIS, BLENREP, BRUKINSA, CARVYKTI, DANZITEN, DARZALEX, ELIQUIS, ELREXFIO, EPKINLY, Fabhalta, Gavreto, IMBRUVICA, IMKELDI, INQOVI, JAKAFI, LONSURF, NIKTIMVO, OJJAARA, PEMGARDA, Polivy, REBLOZYL, REZUROCK, Rezlidhia, SANCUSO, SARCLISA, SCEMBLIX, TALVEY, TAVALISSE, TECVAYLI, Tazverik, VIVIMUSTA, Vanflyta, Venclexta, Vonjo, Vyloy, Yescarta, clonoSEQ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error